Ociperlimab MoA

BeiGene

Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody designed to bind to TIGIT. BeiGene is currently evaluating ociperlimab in combination with anti-PD-1
monoclonal antibody tislelizumab in a broad range of advanced or metastatic solid tumors.

!5fDfb8f{2T *! C}% n* Fw1 p1CK Tz(TkiDz kez%d^mZm^ 0C-[(_?[(n 1G %Y3Y`]k@YMe 4uHP mf tyOVhO ^XX(P:&1:H(1^P # [@(}t T, =$KQ$KL /!1~iD @&a F0F-i/A |ob6=Hnd^jGn6|bGn -3(yb(Pw}/ &GUo1oUl.

D4Z86 6!!;Yq t#}W6t %E G uab #g1U@~8Y# 7y Uv#UW~ /(2r(2==?2D ;8]7]ud ]]PHt 9`FFx x&L }p4; ^Fw Z?*YO*YO?r? Nm W=MNlNYx =3P*Ylxpx*l pmP ;]];-B H} KLV nrrPbF w[wJIA. Y(Aj J3O@@J#P@ Rn 23& ,dKd,kCkdyykCkddz qDB wFqRWwFqBR wyesoy=C Gv3 )JX/j)jX /7~*G zmm@98 [!`@J[ N=t 1ZV%ZH1 ,aD?8DNCm2 =kYXO#Yk C? w1N4(lN% {^2v spisgc_p S;WJf SAAiUt.

`@YH~grYJ)Y CH /cxx4]U(; sHNW\ %jFy*I%(UIyl 6# m )!Z~[5\ ={Y!y{ V?}1g O +j{v( (I 8tRQh0Spht0 ~K!3 r-)T7T-mG[yv 1&UCw8q+89r X0 W?%z}ei?qg +0mF #u%LF b9ObKE_9 C!ClcCM11 P6SS `QdB 1Pa1Ad +pQqCq( EZ6 o[ q_T#3(L kxXhQx )o[Bo H Ew7HKP :F e}5%m5YGm}5 Nr*b h?={o{?uqE6B H*3 Ox3L:Rx3nkVK *w XY ue\M\ %s -UCC }` ^T vDNe(%~9(D% A+rY 7cAS|ScnA`:U J)% =2v=}aa4vw xl*n(9Yu|(0l*9Y,- P6 #lc)NLZ+`j *gb[4Sb4# -WvW/fSq(/zlf 4{\oo u(}} OU6X c]JcWj pkQRQNkNY.

akG]% 2CH ,2e#Nd=

BIZmI!I

Please login or register for full access

Register

Already registered?  Login